Omentin functions to attenuate cardiac hypertrophic response

Journal of Molecular and Cellular Cardiology

Volumn 79, Issue , 2015, Pages 195-202

  Matsuo, Kazuhiro ^a   Shibata, Rei ^a   Ohashi, Koji ^a   Kambara, Takahiro ^a   Uemura, Yusuke ^a   Hiramatsu Ito, Mizuho ^a   Enomoto, Takashi ^a   Yuasa, Daisuke ^a   Joki, Yusuke ^a   Ito, Masanori ^a   Hayakawa, Satoko ^a   Ogawa, Hayato ^a   Kihara, Shinji ^b   Murohara, Toyoaki ^a   Ouchi, Noriyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AMP activated protein kinase; Cardiac hypertrophy; Fibrosis; Omentin

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN II; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; OMENTIN PROTEIN; PHENYLEPHRINE; PLASMA PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CELL SIZE; CONTROLLED STUDY; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; TRANSGENIC MOUSE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE; ANIMAL; AORTA; C57BL MOUSE; CARDIOMEGALY; DRUG EFFECTS; HEART MUSCLE CELL; METABOLISM; OBESITY; PATHOLOGY; SIGNAL TRANSDUCTION; STENOSIS, OCCLUSION AND OBSTRUCTION;

MUS; MUS MUSCULUS;

ADIPOSITY; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; CARDIOMEGALY; CONSTRICTION, PATHOLOGIC; CYTOKINES; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHENYLEPHRINE; RATS; SIGNAL TRANSDUCTION;

EID: 84916918770     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.11.019     Document Type: Article

References (28)

1. Rutter M.K., Parise H., Benjamin E.J., Levy D., Larson M.G., Meigs J.B., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003, 107:448-454.
2. Ilercil A., Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Welty T.K., et al. Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. Am Heart J 2001, 141:992-998.
3. Guerra F., Mancinelli L., Angelini L., Fortunati M., Rappelli A., Dessi-Fulgheri P., et al. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS One 2011, 6:e16630.
4. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
5. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006, 3:35-42.
6. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
7. Tsuji S., Uehori J., Matsumoto M., Suzuki Y., Matsuhisa A., Toyoshima K., et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001, 276:23456-23463.
8. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
9. Shibata R., Ouchi N., Takahashi R., Terakura Y., Ohashi K., Ikeda N., et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012, 4:37.
10. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33.
11. Shibata R., Takahashi R., Kataoka Y., Ohashi K., Ikeda N., Kihara S., et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res 2011, 34:1309-1312.
12. Yoo H.J., Hwang S.Y., Hong H.C., Choi H.Y., Yang S.J., Seo J.A., et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011, 10:103.
13. Shibata R., Ouchi N., Kikuchi R., Takahashi R., Takeshita K., Kataoka Y., et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219:811-814.
14. Zhong X., Zhang H.Y., Tan H., Zhou Y., Liu F.L., Chen F.Q., et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011, 32:873-878.
15. Maruyama S., Shibata R., Kikuchi R., Izumiya Y., Rokutanda T., Araki S., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012, 287:408-417.
16. Yamawaki H., Tsubaki N., Mukohda M., Okada M., Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010, 393:668-672.
17. Kataoka Y., Shibata R., Ohashi K., Kambara T., Enomoto T., Uemura Y., et al. Omentin prevents myocardial ischemic injury through AMPK- and Akt-dependent mechanisms. J Am Coll Cardiol 2014, 63. [2722-233].
18. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
19. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004, 10:1384-1389.
20. Li P., Shibata R., Unno K., Shimano M., Furukawa M., Ohashi T., et al. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Hypertension 2010, 55:69-75.
21. Maruyama S., Shibata R., Ohashi K., Ohashi T., Daida H., Walsh K., et al. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J Biol Chem 2011, 286:32790-32800.
22. Tanaka K., Honda M., Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 2001, 37:676-685.
23. Yue T.L., Gu J.L., Wang C., Reith A.D., Lee J.C., Mirabile R.C., et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000, 275:37895-37901.
24. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004, 279:32771-32779.
25. Kim J., Yoon M.Y., Choi S.L., Kang I., Kim S.S., Kim Y.S., et al. Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J Biol Chem 2001, 276:19102-19110.
26. Yamawaki H., Kuramoto J., Kameshima S., Usui T., Okada M., Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408:339-343.
27. Shibata R., Sato K., Kumada M., Izumiya Y., Sonoda M., Kihara S., et al. Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc Res 2007, 74:471-479.
28. Kazama K., Okada M., Yamawaki H. A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism. Am J Physiol Heart Circ Physiol 2014, 306:H1714-H1719.